Hints of activity, generated by academic centres, suggest that antivirals and an antimalarial might play some role against Covid-19.
Antivirals, anti-interleukins and vaccines take centre stage in clinical trial efforts to tackle the coronavirus pandemic.
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
Earlier this year Glaxosmithkline looked to be going all-in for consumer health domination, but today it moved to leave the space entirely and focus on the thing that…
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…
Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.
Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.